- Home
- MRSN vs RNTX Comparison
MRSN vs RNTX Comparison
Compare MRSN & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- RNTX
- Stock Information
- Founded
- MRSN 2001
- RNTX 2001
- Country
- MRSN United States
- RNTX United States
- Employees
- MRSN N/A
- RNTX N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- MRSN Health Care
- RNTX Health Care
- Exchange
- MRSN Nasdaq
- RNTX Nasdaq
- Market Cap
- MRSN 37.0M
- RNTX 40.3M
- IPO Year
- MRSN 2017
- RNTX N/A
- Fundamental
- Price
- MRSN $7.24
- RNTX $1.10
- Analyst Decision
- MRSN Strong Buy
- RNTX Hold
- Analyst Count
- MRSN 4
- RNTX 1
- Target Price
- MRSN $63.67
- RNTX N/A
- AVG Volume (30 Days)
- MRSN 138.9K
- RNTX 64.4K
- Earning Date
- MRSN 08-13-2025
- RNTX 08-14-2025
- Dividend Yield
- MRSN N/A
- RNTX N/A
- EPS Growth
- MRSN N/A
- RNTX N/A
- EPS
- MRSN N/A
- RNTX N/A
- Revenue
- MRSN $34,769,000.00
- RNTX N/A
- Revenue This Year
- MRSN N/A
- RNTX N/A
- Revenue Next Year
- MRSN $1.03
- RNTX N/A
- P/E Ratio
- MRSN N/A
- RNTX N/A
- Revenue Growth
- MRSN 16.14
- RNTX N/A
- 52 Week Low
- MRSN $5.21
- RNTX $1.04
- 52 Week High
- MRSN $70.75
- RNTX $4.40
- Technical
- Relative Strength Index (RSI)
- MRSN 48.99
- RNTX N/A
- Support Level
- MRSN $5.21
- RNTX N/A
- Resistance Level
- MRSN $7.68
- RNTX N/A
- Average True Range (ATR)
- MRSN 0.54
- RNTX 0.00
- MACD
- MRSN 0.12
- RNTX 0.00
- Stochastic Oscillator
- MRSN 81.04
- RNTX 0.00
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.